Stage III Bladder Cancer AJCC v8 Recruiting Phase 1 / 2 Trials for Tazemetostat (DB12887)

IndicationStatusPhase
DBCOND0109731 (Stage III Bladder Cancer AJCC v8)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03854474Tazemetostat and Pembrolizumab in Treating Patients With Locally Advanced or Metastatic Urothelial CarcinomaTreatment